Cancer Drug Implementation Advisory Committee (CDIAC)

The Cancer Drug Implementation Advisory Committee (CDIAC) is a critical mechanism in our collaborative work to create a more sustainable cancer system. CDIAC’s role is to provide advice, ideally prior to the initiation of pCPA negotiations, about how new drugs can be integrated into existing treatment pathways and to achieve greater consistency in drug funding decisions across Canada. (Figure 1)

Supporting the provinces and aligning with pCODR and pCPA

(Figure 1)

The committee seeks and consolidates clinical expert opinion about potential conditions and criteria for funding by engaging site-specific (e.g. breast or lung) provincial tumour leaders and individual clinical experts. It includes a patient and a family representative to provide a perspective of people with direct experience with the cancer care system. A public representative provides input that reflects public values and perspectives. CDIAC also carefully considers the affordability and budget impact on a provincial and pan-Canadian basis to understand the financial implications of various funding options. (Figure 2)

Steps in CDIAC's process

(Figure 2)

The CDIAC is pan-Canadian and multi-disciplinary and is chaired by a member of the CAPCA Board. It supports the work of pCPA and CADTH/pCODR and INESSS acts as an observer to this committee. For a list of CDIAC members, please click here.